7 terminated. 7 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Terminated 7 |
| Phase 2 | 4 | Terminated 4 |
Follow MDS: new trials by email Literature Review of MDS trials Research Report on MDS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose - AML, Adult Recurrent, ALL, Recurrent, Adult | Phase 1 / Phase 2 | Terminated | BlueSphere Bio, Inc | 2 | 2025-02-04 | 2026-09-10 |
| APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) APR-548 + Azacitidine - MDS, Myelodysplastic Syndromes | Phase 1 | Terminated | Aprea Therapeutics | 4 | 2021-09-20 | 2025-03-10 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies AMG 397, Dexamethasone, Azacitidine - Multiple Myeloma, Acute Myeloid Leukemia | Phase 1 | Terminated | Amgen | 24 | 2018-08-17 | 2023-04-12 |
| A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations E6201 - AML, MDS | Phase 1 / Phase 2 | Terminated | Spirita Oncology, LLC | 27 | 2015-04-10 | 2019-03-20 |
| Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders EPOCH-F/R, FLAG, Transplant Preparative Regimen (Flu/Cy/Mes) - Leukemia, Non-Hodgkins Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 4 | 2009-08-25 | 2019-12-17 |
| A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients Lenalidomide - Myelodysplastic Syndrome, MDS | Phase 1 / Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 8 | 2008-07-01 | 2025-05-04 |
| Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft Naive T-cell Depleted Stem Cell Transplant, Stem Cell Transplant No Manipulation, Isolex device from Baxter - ALL, ANLL | Phase 1 / Phase 2 | Terminated | Duke University | 15 | 2007-07-01 | 2013-11-25 |
Leukemia, Myeloid, Acute (3) · Myelodysplastic Syndromes (3) · Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Hodgkin Disease (1) · Leukemia (1) · Lymphoma (1) · Recurrence (1)
Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Bone Marrow Diseases (3) · Leukemia (3) · Leukemia, Myeloid (3) · Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Hemorrhagic Disorders (2) · Hemostatic Disorders (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2)
Azacitidine (2) · 14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione (1) · Dexamethasone (1) · Lenalidomide (1) · Sirolimus (1) · Tacrolimus (1)
Amgen (1) · Aprea Therapeutics (1) · BlueSphere Bio, Inc (1) · Duke University (1) · National Cancer Institute (NCI) (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Spirita Oncology, LLC (1)
United States (6) · Australia (1) · France (1) · Greece (1) · Italy (1) · Japan (1)
Emmanuel Besa, MD (1) · Gautam Borthakur, MD (1) · Joachim Gullbo, MD (1) · Mitchell Horwitz, MD (1) · Steven Z Pavletic, M.D. (1)